US health authority reprimands large pharmaceutical firms after disagreement on drug discounts
Earlier in the week, the US HRSA sent a letter to many of the largest companies in the pharmaceutical industry concerning their approach to the 340B program which aims to ensure that hospitals get drug discounts.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
The US Department of Health & Human Services (HHS) is cracking down on many of the largest players in the pharmaceutical industry according to healthcare media Endpoints.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EU readies new lawsuit against Astrazeneca over vaccines
For subscribers
Eli Lilly on tirzepatide data: Surpasses our expectations
For subscribers
Sanofi's Dupixent sales grow 45 percent in Q1
For subscribers
.jpg&w=384&q=75)
